On June 24, WuXi Biologics rose 4.24% in regular trading, trading at HKD 32.18/share, with turnover of HKD 128 million.

On the news front, the company has conducted buybacks for three consecutive trading days. From June 18 to June 23, WuXi Biologics repurchased a total of 6.465 million shares at an aggregate cost of approximately HKD 199 million, during which the share price accumulated a gain of 4.29%. Year-to-date, the company has executed 14 rounds of buybacks totaling 34.218 million shares worth HKD 1.072 billion, signaling sustained confidence from management in the company's intrinsic value.

Meanwhile, the Life Sciences Tools and Services sector showed broad-based strength. Among sector peers, GenScript Biotech rose 6.53%, WuXi XDC rose 6.43%, and WuXi AppTec rose 4.28%, reflecting significant sector resonance. Multiple brokerages including CITIC Securities and Guotai Haitong Securities maintain Buy ratings with target prices ranging from HKD 48 to HKD 54.49, well above the current trading level.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)